Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 2/20 | 0.62 |
| ▸ | CTSL | P07711 | 5/20 | 0.61 |
| ▸ | CTSB | P07858 | 3/20 | 0.61 |
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSK | P43235 | 1/20 | 0.61 |
| ▸ | ELANE | P08246 | 2/20 | 0.58 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7620929 | 0.88 | TACR1 (0.65) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL2353877 | 0.88 | ELANE (0.72) | CTSLCTSBCTSSCTSKELANE | |
| SCHEMBL2353879 | 0.88 | ELANE (0.72) | CTSLCTSBCTSSCTSKELANE | |
| SCHEMBL6132175 | 0.86 | TACR1 (0.54) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10802556 | 0.84 | CTSL (0.70) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL19807564 | 0.84 | TACR1 (0.72) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL7275434 | 0.82 | ECE1 (0.65) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL10967811 | 0.82 | CAPN1 (0.72) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL31397615 | 0.82 | CAPN1 (0.72) | TACR1CTSLCTSBCTSSCTSK | |
| SCHEMBL9088735 | 0.82 | CAPN1 (0.72) | TACR1CTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7423012-B2 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-09-09 | — | — | US | disclosed |
| US-7354895-B1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | ASTRAZENECA AB (SE) | 2008-04-08 | — | — | US | disclosed |
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | LINSCHOTEN MARCEL | 2006-04-13 | — | — | US | disclosed |
| EP-1180099-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000066550-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079484-A1 | Phosphinyloxy, oxime and carboxylic acid derivatives which are useful as carboxypeptidase U inhibitors | CPN1, CPA1, DNPEP | TACR1 640/4885CTSL 105/4885CTSB 195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.